Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis

被引:25
|
作者
Wu, Xinle [1 ]
Li, Yang [1 ]
机构
[1] Amgen Inc, 1120 Vet Blvd, San Francisco, CA 94080 USA
来源
AGING-US | 2009年 / 1卷 / 12期
关键词
fibroblast growth factors; FGF19; FGF21; FGF23; aging; diabetes; metabolic diseases; insulin; METABOLIC-ACTIVITY; BETA-KLOTHO; GROWTH; SPECIFICITY; SUPPRESSION; DETERMINES; EXPRESSION; SIGNAL; FAMILY; MODE;
D O I
10.18632/aging.100108
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
FGF19, FGF21, and FGF23 form a unique subfamily of fibroblast growth factors. Because they contain intra molecular disulfide bonds and show reduced affinity toward heparan sulfate located in the extracellular space, it is thought that, in contrast to other FGFs, they function as endocrine hormones. FGF23 and its co-receptor alpha Klotho are involved in the control of aging, but it is not known if the same holds true for FGF19, which can also signal through alpha Klotho. However, considerable evidence supports a role for FGF19 in controlling various aspects of metabolism. We have recently fully characterized FGF19/FGFR/co-factor interactions and signaling, and in the current manuscript discuss the contribution of the FGF19/FGFR4 axis to bile acid and glucose regulation.
引用
收藏
页码:1023 / 1027
页数:5
相关论文
共 50 条
  • [1] Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
    Wu, Xinle
    Ge, Hongfei
    Lemon, Bryan
    Weiszmann, Jennifer
    Gupte, Jamila
    Hawkins, Nessa
    Li, Xiaofan
    Tang, Jie
    Lindberg, Richard
    Li, Yang
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14379 - 14384
  • [2] FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
    Wu, Xinle
    Ge, Hongfei
    Lemon, Bryan
    Vonderfecht, Steven
    Weiszmann, Jennifer
    Hecht, Randy
    Gupte, Jamila
    Hager, Todd
    Wang, Zhulun
    Lindberg, Richard
    Li, Yang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (08) : 5165 - 5170
  • [3] Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer
    Motylewska, Ewelina
    Stepien, Tomasz
    Borkowska, Magdalena
    Kuzdak, Krzysztof
    Siejka, Agnieszka
    Komorowski, Jan
    Stepien, Henryk
    Lawnick, Hanna
    CYTOKINE, 2018, 105 : 32 - 36
  • [4] Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism
    Ge, Hongfei
    Baribault, Helene
    Vonderfecht, Steven
    Lemon, Bryan
    Weiszmann, Jennifer
    Gardner, Jonitha
    Lee, Ki Jeong
    Gupte, Jamila
    Mookherjee, Paramita
    Wang, Minghan
    Sheng, Jackie
    Wu, Xinle
    Li, Yang
    PLOS ONE, 2012, 7 (03):
  • [5] Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
    Yang, Chaofeng
    Jin, Chengliu
    Li, Xiaokun
    Wang, Fen
    McKeehan, Wallace L.
    Luo, Yongde
    PLOS ONE, 2012, 7 (03):
  • [6] FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma
    Gao, Lixia
    Lang, Liwei
    Zhao, Xiangdong
    Shay, Chloe
    Shull, Austin Y.
    Teng, Yong
    ONCOGENE, 2019, 38 (13) : 2394 - 2404
  • [7] Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease
    Chen, Qiang
    Jiang, Yuan
    An, Yuan
    Zhao, Na
    Zhao, Yang
    Yu, Chundong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 409 (04) : 651 - 656
  • [8] Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma
    Zhao, Xuesong
    Joshi, Jaya Julie
    Aird, Daniel
    Karr, Craig
    Yu, Kun
    Huang, Chialing
    Colombo, Federico
    Virrankoski, Milena
    Prajapati, Sudeep
    Selvaraj, Anand
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2733 - +
  • [9] Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL
    Zhu, Z.
    Hu, B.
    Zhu, D.
    Li, X.
    Chen, D.
    Wu, N.
    Rao, Q.
    Zhang, Z.
    Wang, H.
    Zhu, Y.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2025, 48 (01) : 67 - 80
  • [10] Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
    Li, Fan
    Li, Ziming
    Han, Qing
    Cheng, Yirui
    Ji, Wenxiang
    Yang, Ying
    Lu, Shun
    Xia, Weiliang
    ONCOGENE, 2020, 39 (17) : 3507 - 3521